DNAJC5 and malaria: A clinical trial with human Ad subtype 5 (Ad5) encoding CSP and AMA-1 (two different vectors), called NMRC-M3V-Ad-PfC, could not achieve sterile protection after challenge [143] Moreover, boosting resulted in even less malaria-specific immunogenicity, which could be related to the anti-Ad5 response induced by the priming vaccination.